Several studies have been carried out for periodontal diseases and have shown the potential of using IL-1β and TNF-α antagonists, to reduce tissue destruction in periodontal diseases.[10–13] These researchers applied exogenous sIL-1RI and sTNF-RII to the gingival tissues of non-human primates with experimental periodontitis and found inhibition of inflammatory cell infiltration, alveolar bone loss, and loss of tissue attachment. The gene discussed is IL1B; the disease is periodontal disorder.